MedTrace Logo

A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

NCT06497452 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-07-11

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

Glofitamab

Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-12-31
Completion
2026-06-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06497452 on ClinicalTrials.gov